United States FDA Clears Mesoblast Limited (ASX:MSB) Trial For Cervical Spinal Fusion Phase 2
Mesoblast's Phase 2 cervical fusion clinical program will compare two doses of NeoFuse(TM) versus standard-of-care in 36 patients requiring bony fusion at two or more levels in the cervical spine.

Vatican Endorsement Seals NBS's Status as a The Major Play in Regenerative Medicine
Just as we have speculated in articles and trade alerts for the past few weeks, the Roman Catholic church appears to be getting ready to support Neostem's (AMEX:NBS) stem cell initiatives[...]

• NYT > Stem Cells

  MENLO PARK, Calif. (AP) -- Regulators are giving the all-clear to a clinical trial that will test embryonic stem cells as a treatment for spinal cord injury, says the developer of the treatment, Geron Corp.

  Read more...
• Scientific American Topic - Gene Therapy

  Down's syndrome (DS) is an incurable, heritable disorder affecting an estimated 400,000 people in the U.S. It is characterized by impaired cognitive ability and abnormal physical growth. Whereas scientists have long known that DS is caused by inheriting an extra[…]

  Read more...
• Scientific American Topic - Gene Therapy

  In a head-to-head competition held 10 years ago, scientists at the National Institutes of Health tested two promising new types of vaccine to see which might offer the strongest protection against one of the deadliest viruses on earth, the human[…]

  Read more...
• NYT > Stem Cells

  Elaine Fuchs, the new president of the International Society for Stem Cell research, studies the biochemistry of skin tissue.

  Read more...
• Stem Cells Current Events and Stem Cells News from Brightsurf

  Cells from frozen human blood samples can be reprogrammed to an embryonic stem-cell-like state, according to Whitehead Institute researchers. These cells can be multiplied and used to study the genetic and molecular mechanisms of blood disorders and other diseases. (2010-07-02)

  Read more...